ArticleBMC nephrology2026
C3 glomerulonephritis with light chain crystalline podocytopathy and non-crystalline proximal tubulopathy: a case report and integrative clinicopathologic analysis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes a novel renal triad consisting of C3 glomerulonephritis (C3GN), light chain crystalline podocytopathy (LCCP), and non-crystalline light chain proximal tubulopathy (NC-LCPT) in a 41-year-old male presenting with nephrotic syndrome and rapidly progressive renal failure. Investigations revealed monoclonal IgG kappa paraproteinemia and isolated C3 hypocomplementemia. Renal histopathology demonstrated three distinct lesions: (1) C3GN with mesangial and capillary wall C3 deposits; (2) LCCP, featuring intralysosomal κ-restricted crystalline deposits in podocytes; and (3) NC-LCPT, manifesting tubular epithelial injury without crystal formation. This unique combination suggests concurrent and synergistic renal injury resulting from dysregulation of the alternative complement pathway and monoclonal immunoglobulin toxicity, consistent with the spectrum of monoclonal gammopathy of renal significance (MGRS). Although chemotherapy with bortezomib, cyclophosphamide, and prednisone was initiated, treatment was interrupted due to infection. Consequently, the patient progressed to end-stage renal disease within eight months. This case illustrates the aggressive nephrotoxic potential when complement-mediated glomerulopathy coexists with dual monoclonal immunoglobulin-induced glomerular and tubular damage. It emphasizes the critical need for early and integrated therapeutic strategies targeting both the clonal plasma cell population and complement activation to prevent irreversible renal failure. Comprehensive morphological and immunofluorescence analyses are essential for the accurate diagnosis of such complex overlapping nephropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.